Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05884346
Other study ID # APHP230214
Secondary ID 2022-A02455-3823
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2023
Est. completion date May 2024

Study information

Verified date May 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Annie BERGERA
Phone (0)1 44 84 17 24
Email gestion-locale.drc@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart failure with preserved ejection fraction (HPEF, defined as LVEF ≥50%) represents 50% of hospital admissions for heart failure. Although its morbi-mortality is similar to that of heart failure with reduced ejection fraction (HFPEF), it remains an unknown disease with limited data especially from an etiological point of view. The underlying causes are imperfectly understood, and more than half of the patients have HPEF labeled "idiopathic." A non-hierarchical clustering study of HPEF patients led to the identification of a subgroup of patients (25%) with a predominant coronary vascular phenotype (i.e., a history of coronary stenosis with or without the need for revascularization). In these patients, vascular endothelial dysfunction would play a central role in the development and progression of heart failure.One of the mechanisms leading to HPEF could be a decrease in the bioavailability of nitric oxide (NO) involved in the relaxation of the cardiac muscle. As the mechanism of action of NO is pleiotropic, a decrease in NO bioavailability could also be observed at the peripheral level, favoring in the long term the development of unfavorable vascular remodeling, for example in the small digital or retinal arteries.Some HPEF patients could thus be distinguished from others by their predominant "vascular" profile. The link between HPEF and endothelial dysfunction has been suspected but never clearly demonstrated. Ultra-high frequency ultrasound is an innovative technology to estimate the remodeling of small distal arteries in a non-invasive way. The investigators propose to use this imaging on digital arteries in HPEF patients and to study the association with known coronary macrovascular damage.The remodeling parameters will be measured and compared in patients with HPEF with or without identified macrovascular coronary disease.This characterization of arterial remodeling on the digital arteries could be a powerful tool for non-invasive screening in the identification of a subgroup of HPEF that is still considered idiopathic.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 84
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria : Group 1 : - Patients who are = 18 years old - Heart failure with preserved ejection fraction (LVEF = 50%) - B-type natriuretic peptide (BNP) > 35 pg/mL at inclusion - Coronary macrovascular disease (significant coronary stenosis, which may have required revascularization by stenting or coronary bypass surgery). Group 2 : - Patients who are = 18 years old - Heart failure with preserved ejection fraction (LVEF = 50%) - B-type natriuretic peptide (BNP) > 35 pg/mL at screening - Absence of coronary macrovascular disease (no significant coronary atheroma (< 30%) or history of stenting or coronary bypass surgery). Non-inclusion Criteria : Group 1 and group 2 : - Patients under legal protection - Patients not affiliated to a Social Security system - Patient under State Medical Help (France - AME) - Pregnancy or breastfeeding - Refusal or inability to sign consent - Known and treated retinal vasculopathy - Severe or non-stabilized hypertension (BP > 180/100 mmHg at screening) - History of LVEF < 40%.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Ultrahigh-frequency ultrasound
Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease

Locations

Country Name City State
France Hôpital européen Georges Pompidou - AP-HP Paris

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Digital vascular remodeling by ultrahigh-frequency ultrasound The wall-to-lumen ratio of digital arteries recorded with ultrahigh-frequency ultrasound. Day 1
Secondary Radial vascular remodeling by echo-tracking Measurement of peripheral vascular remodeling on radial arteries by arterial distension parameters. Day 1
Secondary Carotid vascular remodeling by echo-tracking Measurement of peripheral vascular remodeling on carotid arteries by arterial distension parameters. Day 1
Secondary Endothelial dysfunction Level of endothelial function measured by arterial flow-mediated vasodilation (FMD, expressed in %). Day 1
Secondary Pulse wave velocity Pulse wave velocity (PWV, velocity expressed in m/s) carotid-femoral (aortic elasticity). Day 1
Secondary Retinal microvascularization To study the retinal microvascularization by Optical Coherence Tomography Angiography (OCT-A) : density measurement per sector (% per studied area). Day 1
Secondary Calcium score Compare the calcium score (expressed by the Agatston score) in patients with heart failure with preserved ejection fraction with or without a priori coronary artery disease. Day 1
See also
  Status Clinical Trial Phase
Suspended NCT05839730 - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05095688 - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting NCT06379152 - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting NCT05676684 - Dapagliflozin, Spironolactone or Both for HFpEF Phase 2/Phase 3
Recruiting NCT04153136 - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study) Phase 2
Recruiting NCT05715697 - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT06114498 - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting NCT04745013 - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart N/A
Completed NCT05126836 - Cilostazol for HFpEF Phase 2
Completed NCT05586828 - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Recruiting NCT04594499 - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting NCT05204238 - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed NCT04535726 - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting NCT03550235 - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed NCT04633460 - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Phase 2
Completed NCT06228807 - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting NCT05284617 - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF Phase 2
Recruiting NCT05562063 - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Phase 4
Recruiting NCT06027307 - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Phase 3
Withdrawn NCT05322616 - Single-Ascending Dose Study of JK07 in Subjects With HFpEF Phase 1